Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
103.30+7.97 (+8.36%)
As of 1:06PM EST. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 95.33 |
| Open | 95.32 |
| Bid | 102.67 x 800 |
| Ask | 102.92 x 900 |
| Day's Range | 94.67 - 103.68 |
| 52 Week Range | 3.65 - 189.40 |
| Volume | 2,535,160 |
| Avg. Volume | 4,280,667 |
| Market Cap | 6.576B |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.66 |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 186.20 |
- Editor's PickYahoo Finance
Coronavirus update: HHS puts vaccine distribution in states' power; Wall Street analysts project lifelong vaccine protection
With three vaccine candidates out with a first look at efficacy data, Wall Street is more optimistic about the light at the end of the pandemic tunnel.
- Motley Fool
3 Long-Shot Coronavirus Vaccine Stocks to Watch in December
Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.
- Yahoo Finance
Coronavirus update: FDA OKs Regeneron antibody EUA; AstraZeneca shows positive vaccine results
U.S. cases surpass 12 million as positive vaccine and antibody treatment news provide hope.
© 2020 Verizon Media. All rights reserved.
